These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24619662)

  • 1. Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells.
    Kaneko M; Nozawa H; Hiyoshi M; Tada N; Murono K; Nirei T; Emoto S; Kishikawa J; Iida Y; Sunami E; Tsuno NH; Kitayama J; Takahashi K; Watanabe T
    J Cancer Res Clin Oncol; 2014 May; 140(5):769-81. PubMed ID: 24619662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells.
    Shiratori H; Kawai K; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Kaneko M; Murono K; Emoto S; Sonoda H; Nozawa H
    Oncol Rep; 2019 Jul; 42(1):377-385. PubMed ID: 31059051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.
    Lin W; Zheng L; Zhuang Q; Zhao J; Cao Z; Zeng J; Lin S; Xu W; Peng J
    BMC Complement Altern Med; 2013 Jun; 13():144. PubMed ID: 23800091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RA-XII, a bicyclic hexapeptidic glucoside isolated from Rubia yunnanensis Diels, exerts antitumor activity by inhibiting protective autophagy and activating Akt-mTOR pathway in colorectal cancer cells.
    Wang J; Wang J; Li L; Feng L; Wang YR; Wang Z; Tan NH
    J Ethnopharmacol; 2021 Feb; 266():113438. PubMed ID: 33017635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatory anti-tumor activities of 1,4-bis[2-(dimethylamino)ethylamino]-5,8-dihydroxyanthracene-9,10-dione (AQ4) and temsirolimus against colorectal cancer cells.
    Okamoto K; Nozawa H; Sonoda H; Kaneko M; Ishihara S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4689-4699. PubMed ID: 36220941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fangchinoline exerts anticancer effects on colorectal cancer by inducing autophagy via regulation AMPK/mTOR/ULK1 pathway.
    Xiang X; Tian Y; Hu J; Xiong R; Bautista M; Deng L; Yue Q; Li Y; Kuang W; Li J; Liu K; Yu C; Feng G
    Biochem Pharmacol; 2021 Apr; 186():114475. PubMed ID: 33609560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
    Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
    Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
    Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S
    PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
    Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
    Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2/STAT3 (T705) and mTOR/STAT3 (S727) signaling pathways in colorectal cancer.
    Zhang ZH; Li MY; Wang Z; Zuo HX; Wang JY; Xing Y; Jin C; Xu G; Piao L; Piao H; Ma J; Jin X
    Phytomedicine; 2020 Mar; 68():153172. PubMed ID: 32004989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
    Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
    Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma.
    Jia L; Wang J; Wu T; Wu J; Ling J; Cheng B
    Mol Med Rep; 2017 Nov; 16(5):5779-5786. PubMed ID: 28849182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
    Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
    Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
    Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.